D Ross Camidge1. 1. Developmental Therapeutics and Thoracic Oncology Programs, Department of Medical Oncology, University of Colorado Denver, Aurora, CO 80045-0508, USA. Ross.Camidge@UCHSC.edu
Abstract
BACKGROUND: Apomab is a pro-apoptotic anticancer agonist monoclonal antibody against Death receptor 5 (DR5)/TNF-related apoptosis inducing ligand-receptor 2 (TRAIL-R2). OBJECTIVE: To review available preclinical and clinical data and compare Apomab with similar agents. METHODS: Manuscripts were identified (PubMed) using the terms TRAIL-R2, DR5 and Apomab. Abstracts from major oncology meetings in 2005 - 2008 were hand-searched. RESULTS/ CONCLUSION: Apomab demonstrates preclinical activity against a range of solid tumors, both as monotherapy and in combination with cytotoxics. Clinical data are limited but Apomab exposures appear compatible with intermittent dosing alongside standard chemotherapy regimens. Transaminitis has been noted in 1 out of 37 patients but the true frequency and severity of this and other toxicities cannot yet be determined. Apomab has shown early signs of anticancer activity in heavily pretreated patients. Several similar agents are at similar stages of development. No direct comparisons have yet been undertaken but potential differences between these agents are discussed.
BACKGROUND: Apomab is a pro-apoptotic anticancer agonist monoclonal antibody against Death receptor 5 (DR5)/TNF-related apoptosis inducing ligand-receptor 2 (TRAIL-R2). OBJECTIVE: To review available preclinical and clinical data and compare Apomab with similar agents. METHODS: Manuscripts were identified (PubMed) using the terms TRAIL-R2, DR5 and Apomab. Abstracts from major oncology meetings in 2005 - 2008 were hand-searched. RESULTS/ CONCLUSION: Apomab demonstrates preclinical activity against a range of solid tumors, both as monotherapy and in combination with cytotoxics. Clinical data are limited but Apomab exposures appear compatible with intermittent dosing alongside standard chemotherapy regimens. Transaminitis has been noted in 1 out of 37 patients but the true frequency and severity of this and other toxicities cannot yet be determined. Apomab has shown early signs of anticancer activity in heavily pretreated patients. Several similar agents are at similar stages of development. No direct comparisons have yet been undertaken but potential differences between these agents are discussed.
Authors: Danielle F Eytan; Grace E Snow; Sophie G Carlson; Stephen Schiltz; Zhong Chen; Carter Van Waes Journal: Laryngoscope Date: 2014-11-28 Impact factor: 3.325
Authors: Tanmoy Mondal; Gururaj N Shivange; Rachisan Gt Tihagam; Evan Lyerly; Michael Battista; Divpriya Talwar; Roxanna Mosavian; Karol Urbanek; Narmeen S Rashid; J Chuck Harrell; Paula D Bos; Edward B Stelow; M Sharon Stack; Sanchita Bhatnagar; Jogender Tushir-Singh Journal: EMBO Mol Med Date: 2021-02-15 Impact factor: 12.137
Authors: Niklas K Finnberg; Prashanth Gokare; Arunasalam Navaraj; Krystle A Lang Kuhs; George Cerniglia; Hideo Yagita; Kazuyoshi Takeda; Noboru Motoyama; Wafik S El-Deiry Journal: Cancer Res Date: 2015-11-25 Impact factor: 12.701
Authors: Irene Zinonos; Agatha Labrinidis; Michelle Lee; Vasilios Liapis; Shelley Hay; Vladimir Ponomarev; Peter Diamond; Andrew C W Zannettino; David M Findlay; Andreas Evdokiou Journal: Mol Cancer Ther Date: 2009-10-06 Impact factor: 6.261